Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibition
作者:Mayuko Akiu、Takashi Tsuji、Yoshitaka Sogawa、Koji Terayama、Mika Yokoyama、Jun Tanaka、Daigo Asano、Ken Sakurai、Eduard Sergienko、E. Hampton Sessions、Stephen J. Gardell、Anthony B. Pinkerton、Tsuyoshi Nakamura
DOI:10.1016/j.bmcl.2021.128048
日期:2021.7
identified as potent NAMPT activators. Early optimization of HTS hits afforded compound 12, with a triazolopyridine core, as a lead compound. CYP direct inhibition (DI) was identified as an issue of concern, and was resolved through modulation of lipophilicity to culminate in 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea (21), which showed potent NAMPT activity
烟酰胺磷酸核糖基转移酶 (NAMPT) 催化 NAD +补救途径的限速步骤。由于 NAD +在包括新陈代谢和衰老在内的许多生物过程中起着关键作用,因此 NAMPT 的激活是治疗多种疾病的有吸引力的治疗靶点。在此,我们报告了新型含尿素衍生物的持续优化,这些衍生物被鉴定为有效的 NAMPT 激活剂。HTS 命中的早期优化提供了具有三唑并吡啶核心的化合物12作为先导化合物。CYP 直接抑制 (DI) 被确定为一个令人关注的问题,并通过调节亲脂性以最终形成 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4] 来解决三唑并[1,5- a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea ( 21 ),它显示出有效的 NAMPT 活性,同时对多种 CYP 同工型的 CYP DI 减弱。